Log in

NASDAQ:AKBAAkebia Therapeutics Stock Price, Forecast & News

-0.27 (-2.17 %)
(As of 05/25/2020 04:00 PM ET)
Today's Range
Now: $12.16
50-Day Range
MA: $9.21
52-Week Range
Now: $12.16
Volume689,562 shs
Average Volume1.63 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
Akebia Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AKBA



Sales & Book Value

Annual Sales$335 million
Book Value$3.32 per share


Net Income$-279,660,000.00


Market Cap$1.58 billion
Next Earnings Date8/13/2020 (Estimated)

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

How has Akebia Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AKBA stock has increased by 75.2% and is now trading at $12.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Akebia Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akebia Therapeutics.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Akebia Therapeutics.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc (NASDAQ:AKBA) released its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.62) by $0.15. The biopharmaceutical company earned $88.48 million during the quarter, compared to analysts' expectations of $77.54 million. Akebia Therapeutics had a negative return on equity of 45.52% and a negative net margin of 76.39%. View Akebia Therapeutics' earnings history.

What price target have analysts set for AKBA?

6 analysts have issued 1-year price objectives for Akebia Therapeutics' stock. Their forecasts range from $11.00 to $18.00. On average, they expect Akebia Therapeutics' stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price. View analysts' price targets for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (5/12/2020)
  • 2. HC Wainwright analysts commented, "We continue to believe that positive outcomes, on both safety and efficacy, from all four studies is highly likely, and with data directly comparing its outcomes to the current standard of care in both DD and NDD patients, we continue to believe Akebia is well positioned for clinical, regulatory and commercial success. Affirm Buy. $17 PT. We employ a rNPV model, driven by U.S. sales of vadadustat (early 2022 launch, 75% POS, $2.5B peak U.S. sales) and Auryxia (peak sales of $409M in 2024) out to 2028 (zero terminal value) discounted at 12.5%. Risks to our investment thesis and target price include: (1) failure in pivotal Phase 3 vadadustat studies; (2) failure to secure regulatory approval of vadadustat; (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing; and (4) intellectual property opposition." (9/9/2019)

Has Akebia Therapeutics been receiving favorable news coverage?

Media coverage about AKBA stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Akebia Therapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAkebia Therapeutics.

Who are some of Akebia Therapeutics' key competitors?

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), Chesapeake Energy (CHK), Energy Transfer LP Unit (ET), AbbVie (ABBV), FireEye (FEYE), TherapeuticsMD (TXMD), Bank of America (BAC), Corbus Pharmaceuticals (CRBP) and NVIDIA (NVDA).

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)
  • Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
  • Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
  • Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)
  • Mr. Douglas Jermasek, VP of Marketing & Strategy

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baupost Group LLC MA (13.46%), BlackRock Inc. (7.78%), State Street Corp (2.62%), Geode Capital Management LLC (1.40%), Wellington Management Group LLP (1.32%) and Nuveen Asset Management LLC (1.14%). Company insiders that own Akebia Therapeutics stock include Jason Amello, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. View institutional ownership trends for Akebia Therapeutics.

Which institutional investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, Morgan Stanley, Nuveen Asset Management LLC, Clearbridge Investments LLC, BlackRock Inc., Bank of New York Mellon Corp, AQR Capital Management LLC, and UBS Group AG. Company insiders that have sold Akebia Therapeutics company stock in the last year include Jason Amello, Michel Dahan, and Nicole R Hadas. View insider buying and selling activity for Akebia Therapeutics.

Which institutional investors are buying Akebia Therapeutics stock?

AKBA stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Wellington Management Group LLP, Atom Investors LP, Geode Capital Management LLC, Deutsche Bank AG, Virginia Retirement Systems ET AL, Squarepoint Ops LLC, and Trexquant Investment LP. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke. View insider buying and selling activity for Akebia Therapeutics.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $12.16.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $1.58 billion and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is www.akebia.com.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.